Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee-Reference-Cited by-同舟云学术

Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee

Published:2021-05 Issue:2 Volume:161 Page:502-507
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Kurtz Jean-Emmanuel,Gebski Val,Sukhin Vladyslav,Carey Mark,Kong Iwa,Glasspool Rosalind M.,Berek Jonathan S.,de Paiva Batista Mariana,Hall Marcia,Kim Jae-Weon,Yeoshoua Effi,Fujiwara Noriko,Nam Byung-Ho,Polleis Sandra,Lee Jung-Yun,Strojna Aleksandra,Farrelly Laura,Schwameis Richard,Fossati Roldano,Darlington Anne-Sophie,Lai Chyong-Huey,Wright Alexi A.,Rosenblat Orgad,Harter Phillip,Roxburgh Patricia,Chowdhury Rahul Roy,Chang Ting-Chang,Paoletti Xavier,Friedlander Michael

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference27 articles.

1. 5th Ovarian Cancer Consensus Conference. Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference;Bookman;Ann. Oncol.,2017

2. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards;Brundage;Qual. Life Res.,2013

3. Brundage MD; CONSORT PRO group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension;Calvert;JAMA.,2013

4. A new index of priority symptoms in advanced ovarian cancer;Jensen;Gynecol. Oncol.,2011

5. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology;Aaronson;JNCI J. National Cancer Instit.,1993

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice;Patient Related Outcome Measures;2023-05

2. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study;International Journal of Gynecologic Cancer;2022-01-27

3. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial;Therapeutic Advances in Medical Oncology;2022-01